Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1

eLife

Volumn 2012, Issue 1, 2012, Pages

  Denard, Bray ^a   Lee, Ching ^a   Ye, Jin ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALNEXIN; CERAMIDE; COLLAGEN TYPE 1; DNA TOPOISOMERASE; DOXORUBICIN; FUMONISIN B1; LYSINE SPECIFIC DEMETHYLASE 1; NUCLEAR PROTEIN; PROTEIN P21; SERINE PALMITOYLTRANSFERASE; THERMOZYMOCIDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CREB3L1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CREB3L1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MBTPS2 PROTEIN, HUMAN; MEMBRANE-BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1; METALLOPROTEINASE; NERVE PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; TUMOR MARKER;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MASS SPECTROMETRY; NICK END LABELING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CELL CYCLE; CHO CELL LINE; CRICETULUS; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDES; CHO CELLS; CRICETULUS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METALLOENDOPEPTIDASES; NERVE TISSUE PROTEINS; PROPROTEIN CONVERTASES; PROTEOLYSIS; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84881522110     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00090     Document Type: Article

References (36)

1. Adams CM, Reitz J, De Brabander JK, Feramisco JD, Li L, Brown MS, et al. 2004. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 279:52772-80.
2. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. 1995. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 82:405-14.
3. Brown MS, Goldstein JL. 2009. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 50:S15-27.
4. Brown MS, Ye J, Rawson RB, Goldstein JL. 2000. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 100:391-8.
5. DeBose-Boyd RA, Brown MS, Li WP, Nohturfft A, Goldstein JL, Espenshade PJ. 1999. Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 99:703-12.
6. Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y, et al. 2011. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe 10:65-74.
7. Gault C, Obeid L, Hannun YA. 2010. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1-23.
8. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-41.
9. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100:12027-32.
10. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. 1993. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14:987-92.
11. Kitatani K, Idkowiak-Baldys J, Hannun YA. 2008. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20:1010-8.
12. Lee V, Harris D. 2011. Adriamycin nephropathy: A model of focal segmental glomerulosclerosis. Nephrology 16:30-8.
13. Levine AJ, Momand J, Finlay CA. 1991. The p53 tumour suppressor gene. Nature 351:453-6.
14. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 277:9520-8.
15. Linn SC, Kim HS, Keane EM, Andras LM, Wang E, Merrill AH. 2001. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem Soc Trans 29:831-5.
16. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, et al. 2008. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22:2541-51.
17. Lupi M, Matera G, Natoli C, Colombo V, Ubezio P. 2007. The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 6:943-50.
18. Metherall JE, Goldstein JL, Luskey KL, Brown MS. 1989. Loss of transcriptional repression of three sterol-regulated genes in mutant hamster cells. J Biol Chem 264:15634-41.
19. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. 1995. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 211:396-403.
20. Mullen TD, Hannun YA, Obeid LM. 2012. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J 441:789-802.
21. Murakami T, Kondo S, Ogata M, Kanemoto S, Saito A, Wanaka A, et al. 2006. Cleavage of the membrane-bound transcription factor OASIS in response to endoplasmic reticulum stress. J Neurochem 96:1090-100.
22. Murakami T, Saito A, Hino S, Kondo S, Kanemoto S, Chihara K, et al. 2009. Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat Cell Biol 11:1205-11.
23. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 42:3858-63.
24. Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ. 2000. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 102:315-23.
25. Ogretmen B, Hannun YA. 2004. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-16.
26. Omori Y, Imai J, Suzuki Y, Watanabe S, Tanigami A, Sugano S. 2002. OASIS is a transcriptional activator of CREB/ATF family with a transmembrane domain. Biochem Biophys Res Commun 293:470-7.
27. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. 2008. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab 8:512-21.
28. Rawson RB, Zelenski NG, Nijhawan D, Ye J, Sakai J, Hasan MT, et al. 1997. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol Cell 1:47-57.
29. Rawson RB, Cheng D, Brown MS, Goldstein JL. 1998. Isolation of cholesterol-requiring mutant Chinese hamster ovary cells with defects in cleavage of sterol regulatory element-binding proteins at site 1. J Biol Chem 273:28261-9.
30. Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL. 1996. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85:1037-46.
31. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-12.
32. Soule HD, Vazguez J, Long A, Albert S, Brennan M. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409-16.
33. Stähelin HF, von Wartburg A. 1991. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture. Cancer Res 51:5-15.
34. Wang E, Norred WP, Bacon CW, Riley RT, Merrill AH. 1991. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J Biol Chem 266:14486-90.
35. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, et al. 1984. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39:27-38.
36. Ye J, Dave UP, Grishin NV, Goldstein JL, Brown MS. 2000. Asparagine-proline sequence within membrane-spanning segment of SREBP triggers intramembrane cleavage by site-2 protease. Proc Natl Acad Sci USA 97:5123-8.